Mark R. Silvis

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-0717-1983

Also affiliated with University of Utah, Huntsman Cancer Institute

ChemistryMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition”.

MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition

The Journal of Experimental Medicine(2023)10.1084/jem.20221524

N/A

0DataRank · unranked

50 citations

Dilru Silva, Riley Rohweder, Sophia Schuman, Swapna Aravind Gudipaty, Amanda Truong +5 more

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

eLife(2024)10.7554/elife.96992

N/A

0DataRank · unranked

13 citations

Kayla O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang +8 more

Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.06.579200

N/A

0DataRank · unranked

3 citations

Kayla O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang +8 more